Evidence map›Paper›PMID 39093547›Full record

ArticleMolecular diagnosis & therapy2024

Performance of a Rapid Digital PCR Test for the Detection of Non-Small Cell Lung Cancer (NSCLC) Variants.

Abdulaziz F Al Mana, Kristen Culp, Abby Keeler, Orlando Perrera, Malini Rajagopalan, Lucien Jacky, Brad Brown, Bharat Thyagarajan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdulaziz F Al ManaDepartment of Laboratory Medicine and Pathology, University of Minnesota, 100 Church St SE, Minneapolis, MN, 55455, USA.ORCID 0000-0003-1287-0823
Kristen CulpChromaCode, Inc., Carlsbad, CA, USA.
Abby KeelerDepartment of Laboratory Medicine and Pathology, University of Minnesota, 100 Church St SE, Minneapolis, MN, 55455, USA.
Orlando PerreraChromaCode, Inc., Carlsbad, CA, USA.
Malini RajagopalanChromaCode, Inc., Carlsbad, CA, USA.
Lucien JackyChromaCode, Inc., Carlsbad, CA, USA.
Brad BrownChromaCode, Inc., Carlsbad, CA, USA.
Bharat ThyagarajanDepartment of Laboratory Medicine and Pathology, University of Minnesota, 100 Church St SE, Minneapolis, MN, 55455, USA. thya0003@umn.edu.ORCID 0000-0001-6968-6985

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNext-generation sequencing is widely used for comprehensive molecular profiling for many cancers including lung cancer. However, the complex workflows and long turnaround times limit its access and utility. ChromaCode's High Definition PCR Non-Small Cell Lung Cancer Panel (HDPCR™ NSCLC Panel) is a low-cost, rapid turnaround, digital polymerase chain reaction assay that is designed to detect variants in nine NSCLC genes listed in National Comprehensive Cancer Network guidelines.

methodsThis assay uses TaqMan

resultsThe overall accuracy of the HDPCR panel was 99.48% (95% confidence interval 99.01-99.76) with a sensitivity of 95.35% (95% confidence interval 88.52-98.72) and a specificity of 99.69% (95% confidence interval 99.29-99.90). The HDPCR wet lab workflow was 4 h, and the time to generate variant calls from raw data using the ChromaCode Cloud was 2 minutes.

conclusionsWe demonstrated that the HDPCR™ NSCLC Panel provides timely, comprehensive, and sensitive mutation detection in NSCLC samples with results in less than 24 h.

Indexed as

Carcinoma, Non-Small-Cell LungHigh-Throughput Nucleotide SequencingLung NeoplasmsPolymerase Chain ReactionBiomarkers, TumorHumansMutationSensitivity and SpecificityBiomarkers, Tumor

Identifiers

PMID39093547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.